Everything we've seen

1. ?Sep 14, 3:20 PMdecisionconsidered

   Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

   XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

2. !Sep 14, 3:20 PMsignalseverity 0.27

   Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

   XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

3. ?Sep 14, 2:20 PMdecisionconsidered

   Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

   XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

4. !Sep 14, 2:20 PMsignalseverity 0.28

   Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

   XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

5. ?Sep 14, 1:20 PMdecisionconsidered

   Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

   XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

6. !Sep 14, 1:20 PMsignalseverity 0.28

   Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

   XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

7. ?Sep 14, 12:20 PMdecisionconsidered

   Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

   XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

8. !Sep 14, 12:20 PMsignalseverity 0.26

   Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

   XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

9. ?Sep 14, 11:21 AMdecisionconsidered

   Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

   XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

10. !Sep 14, 11:21 AMsignalseverity 0.27

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

11. ?Sep 14, 10:21 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

12. !Sep 14, 10:21 AMsignalseverity 0.27

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

13. ?Sep 14, 7:00 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

14. !Sep 14, 7:00 AMsignalseverity 0.27

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

15. ?Sep 11, 6:04 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    XRAY (Dentsply Sirona) appears on a "stocks to steer clear of" list with negative sentiment (-0.35), suggesting company-specific concerns rather than a broad market selloff. The 10-Q and 8-K filings from early August lack detailed metrics in the provided data, making it difficult to confirm financial health, but the combination of a 27.1% drop and negative editorial coverage points to underlying deterioration rather than a mere macro-driven dip. Additionally, the elevated 5-year forward inflation rate (2.34, 1.8σ above trend) creates a headwind for rate-sensitive and consumer-discretionary-adjacent healthcare names.

16. !Sep 11, 6:04 PMsignalseverity 0.27

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    XRAY (Dentsply Sirona) appears on a "stocks to steer clear of" list with negative sentiment (-0.35), suggesting company-specific concerns rather than a broad market selloff. The 10-Q and 8-K filings from early August lack detailed metrics in the provided data, making it difficult to confirm financial health, but the combination of a 27.1% drop and negative editorial coverage points to underlying deterioration rather than a mere macro-driven dip. Additionally, the elevated 5-year forward inflation rate (2.34, 1.8σ above trend) creates a headwind for rate-sensitive and consumer-discretionary-adjacent healthcare names.

17. ?Sep 11, 4:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

18. !Sep 11, 4:20 PMsignalseverity 0.27

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

19. ?Sep 11, 3:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

20. !Sep 11, 3:20 PMsignalseverity 0.28

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

21. ?Sep 11, 2:21 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

22. !Sep 11, 2:21 PMsignalseverity 0.28

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

23. ?Sep 11, 1:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

24. !Sep 11, 1:20 PMsignalseverity 0.28

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

25. ❖Sep 11, 1:15 PMnewsvia finnhub

    3 Russell 2000 Stocks We Steer Clear Of

    The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.

26. ?Sep 11, 12:21 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

27. !Sep 11, 12:21 PMsignalseverity 0.28

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

28. ?Sep 10, 4:26 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

29. !Sep 10, 4:26 PMsignalseverity 0.27

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

30. ?Sep 10, 3:11 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    XRAY is down ~2% with only 35 minutes remaining until the forced close. The move is meaningful but the setup has several headwinds for continuation: (1) Time is extremely limited — 35 minutes is barely enough runway for a clean continuation trade, and the forced flatten at 3:45 PM ET caps any potential. (2) No news catalyst is present to explain the move or sustain seller conviction into the close; without a known driver, late-session fades are common as intraday sellers take profits. (3) The macro context (5Y5Y inflation forward 1.6σ above trend) is modestly risk-off for rate-sensitive sectors, which could provide mild support for the down move, but XRAY (dental products) is not a primary rate-sensitive name. (4) With the stock already at $10.51 and a -1.5% stop on a short, the downside target would be ~$10.82 reversal risk versus a +3% target near $10.20 — the math is acceptable but the time constraint is the binding issue. On balance, the short time remaining and lack of a clear catalyst tip this below the 0.5 threshold despite the momentum signal.

31. !Sep 10, 3:11 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    XRAY is down ~2% with only 35 minutes remaining until the forced close. The move is meaningful but the setup has several headwinds for continuation: (1) Time is extremely limited — 35 minutes is barely enough runway for a clean continuation trade, and the forced flatten at 3:45 PM ET caps any potential. (2) No news catalyst is present to explain the move or sustain seller conviction into the close; without a known driver, late-session fades are common as intraday sellers take profits. (3) The macro context (5Y5Y inflation forward 1.6σ above trend) is modestly risk-off for rate-sensitive sectors, which could provide mild support for the down move, but XRAY (dental products) is not a primary rate-sensitive name. (4) With the stock already at $10.51 and a -1.5% stop on a short, the downside target would be ~$10.82 reversal risk versus a +3% target near $10.20 — the math is acceptable but the time constraint is the binding issue. On balance, the short time remaining and lack of a clear catalyst tip this below the 0.5 threshold despite the momentum signal.

32. ?Sep 10, 1:06 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    XRAY is down 1.54% with no catalyzing news headlines, which limits conviction on the move's origin. The macro context shows 5-year forward inflation expectations (T5YIFR) elevated 1.6σ above trend — modestly negative for rate-sensitive sectors broadly, but XRAY (dental supplies) has limited direct rate sensitivity. The move itself is below the 2% threshold that would signal strong institutional conviction, leaving open the possibility this is noise or thin-session drift rather than directional flow. With 159 minutes remaining there is time for continuation, but without a news driver or clear sector pressure to sustain selling, the probability of continuation into the close is slightly below the 0.5 trigger threshold. The risk-reward doesn't justify a short position here given the ambiguity of the catalyst and the relatively modest move size.

33. !Sep 10, 1:06 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    XRAY is down 1.54% with no catalyzing news headlines, which limits conviction on the move's origin. The macro context shows 5-year forward inflation expectations (T5YIFR) elevated 1.6σ above trend — modestly negative for rate-sensitive sectors broadly, but XRAY (dental supplies) has limited direct rate sensitivity. The move itself is below the 2% threshold that would signal strong institutional conviction, leaving open the possibility this is noise or thin-session drift rather than directional flow. With 159 minutes remaining there is time for continuation, but without a news driver or clear sector pressure to sustain selling, the probability of continuation into the close is slightly below the 0.5 trigger threshold. The risk-reward doesn't justify a short position here given the ambiguity of the catalyst and the relatively modest move size.

34. ?Sep 10, 11:20 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    XRAY is down 1.54% today with no attributable news catalyst. The move is modest — below the 2% threshold that would signal strong institutional conviction — and no headlines provide directional clarity. The macro context shows the 5-year forward inflation rate (T5YIFR) running 1.6σ above its 24-month trend, which creates a headwind for rate-sensitive sectors broadly; however, XRAY (Dentsply Sirona, dental equipment) is not a primary rate-sensitive name, so macro tailwind/headwind is limited here. With 265 minutes remaining there is ample time for continuation, but also ample time for mean reversion on a move without a clear catalyst. The absence of news is not disqualifying, but a sub-2% drift lower without volume confirmation or sector sympathy is more consistent with a random intraday fluctuation than sustained directional pressure. The elevated inflation expectations environment could create some mild further pressure on discretionary/healthcare spend sentiment, but this is speculative. Net assessment: slightly more likely to fade or be uncertain than to continue — probability falls just below the 0.5 trigger threshold.

35. !Sep 10, 11:20 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    XRAY is down 1.54% today with no attributable news catalyst. The move is modest — below the 2% threshold that would signal strong institutional conviction — and no headlines provide directional clarity. The macro context shows the 5-year forward inflation rate (T5YIFR) running 1.6σ above its 24-month trend, which creates a headwind for rate-sensitive sectors broadly; however, XRAY (Dentsply Sirona, dental equipment) is not a primary rate-sensitive name, so macro tailwind/headwind is limited here. With 265 minutes remaining there is ample time for continuation, but also ample time for mean reversion on a move without a clear catalyst. The absence of news is not disqualifying, but a sub-2% drift lower without volume confirmation or sector sympathy is more consistent with a random intraday fluctuation than sustained directional pressure. The elevated inflation expectations environment could create some mild further pressure on discretionary/healthcare spend sentiment, but this is speculative. Net assessment: slightly more likely to fade or be uncertain than to continue — probability falls just below the 0.5 trigger threshold.

36. ?Sep 10, 9:40 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    XRAY is down -1.68% today with no news catalyst identified. The move is modest (below the 2-5% threshold that would signal strong conviction flow), which limits confidence in sustained directional pressure. The macro context shows T5YIFR elevated at 1.6σ above trend — rate-sensitive sectors face headwinds broadly, which could mildly support continued weakness in a rate-sensitive name, but XRAY (dental products) is not a primary rate-sensitive sector. With 365 minutes remaining (essentially a full remaining session), there is ample time for either continuation or reversal, but the absence of a news catalyst and the sub-2% magnitude suggest this may be noise or thin-volume drift rather than a conviction-driven move. No reversal signals are evident, but equally no strong continuation pressure. This sits just below the 0.5 threshold — the move lacks sufficient evidence of sustained institutional selling pressure to warrant a continuation trade.

37. !Sep 10, 9:40 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    XRAY is down -1.68% today with no news catalyst identified. The move is modest (below the 2-5% threshold that would signal strong conviction flow), which limits confidence in sustained directional pressure. The macro context shows T5YIFR elevated at 1.6σ above trend — rate-sensitive sectors face headwinds broadly, which could mildly support continued weakness in a rate-sensitive name, but XRAY (dental products) is not a primary rate-sensitive sector. With 365 minutes remaining (essentially a full remaining session), there is ample time for either continuation or reversal, but the absence of a news catalyst and the sub-2% magnitude suggest this may be noise or thin-volume drift rather than a conviction-driven move. No reversal signals are evident, but equally no strong continuation pressure. This sits just below the 0.5 threshold — the move lacks sufficient evidence of sustained institutional selling pressure to warrant a continuation trade.

38. ?Sep 9, 4:25 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

39. !Sep 9, 4:25 PMsignalseverity 0.26

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

40. ?Sep 8, 4:22 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

41. !Sep 8, 4:22 PMsignalseverity 0.24

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

42. ?Sep 8, 1:24 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

43. !Sep 8, 1:24 PMsignalseverity 0.23

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

44. ❖Sep 8, 12:13 PMnewsvia finnhub

    XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure

    XRAY beat Q2 earnings and revenue estimates, held 2026 guidance and improved cash flow, but falling sales and margin pressure cloud the recovery.

45. ?Sep 8, 11:25 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

46. !Sep 8, 11:25 AMsignalseverity 0.24

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY (Dentsply Sirona) is down 24.2% from its 30-day high with no news headlines, no insider buying, no options flow, and 10-Q/8-K filings with empty metrics — leaving the cause of the drop entirely unexplained. The Health Care sector is a relative outperformer (rank 3/11, +1.23pts vs SPY over 30d), meaning this is an idiosyncratic drop rather than sector-driven selling, which raises concern about unconfirmed company-specific deterioration. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst catalysts) and no visibility into fundamentals from the empty SEC filing metrics, there is insufficient evidence to characterize this as a clear overreaction with identifiable recovery catalyst.

47. ?Sep 8, 10:10 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    XRAY is down 2.24% intraday with no attributable headline catalyst, suggesting the move is driven by technical selling or broad sector pressure rather than a specific news event. The macro context shows 5-year forward inflation expectations elevated at 1.7σ above trend, which generally pressures rate-sensitive and growth sectors but has ambiguous impact on a dental products/healthcare name like XRAY. With 335 minutes remaining (effectively most of the trading day still ahead), there is ample time for continuation, but also ample time for mean reversion. The absence of news makes it harder to assess whether institutional flow has fully played out or is ongoing. The move at 2.24% sits at the lower bound of the 2-5% 'meaningful conviction' range, providing only moderate evidence of sustained directional flow. No reversal signal is evident, but no strong continuation catalyst is present either. This is a borderline setup — slight lean toward continuation given time remaining and the principle that borderline reads should resolve toward the trade, but confidence is minimal.

48. !Sep 8, 10:10 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    XRAY is down 2.24% intraday with no attributable headline catalyst, suggesting the move is driven by technical selling or broad sector pressure rather than a specific news event. The macro context shows 5-year forward inflation expectations elevated at 1.7σ above trend, which generally pressures rate-sensitive and growth sectors but has ambiguous impact on a dental products/healthcare name like XRAY. With 335 minutes remaining (effectively most of the trading day still ahead), there is ample time for continuation, but also ample time for mean reversion. The absence of news makes it harder to assess whether institutional flow has fully played out or is ongoing. The move at 2.24% sits at the lower bound of the 2-5% 'meaningful conviction' range, providing only moderate evidence of sustained directional flow. No reversal signal is evident, but no strong continuation catalyst is present either. This is a borderline setup — slight lean toward continuation given time remaining and the principle that borderline reads should resolve toward the trade, but confidence is minimal.

49. ?Sep 4, 7:23 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    XRAY has returned to profitability per recent headlines, which is a positive sign, but sentiment scores are tepid (0.25 and 0.05), and the stock is described as potentially still trading at a discount — suggesting the market isn't yet convinced of a sustained recovery. The 21.2% drawdown from the 30-day high is meaningful, but no catastrophic deterioration (fraud, guidance cut, accounting issues) is evident in the filings or news. However, the macro backdrop is a mild headwind: the 5-year forward inflation rate is running 1.7σ above trend, pressuring rate-sensitive and consumer-facing sectors like dental equipment, which could weigh on multiple expansion.

50. !Sep 4, 7:23 PMsignalseverity 0.21

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    XRAY has returned to profitability per recent headlines, which is a positive sign, but sentiment scores are tepid (0.25 and 0.05), and the stock is described as potentially still trading at a discount — suggesting the market isn't yet convinced of a sustained recovery. The 21.2% drawdown from the 30-day high is meaningful, but no catastrophic deterioration (fraud, guidance cut, accounting issues) is evident in the filings or news. However, the macro backdrop is a mild headwind: the 5-year forward inflation rate is running 1.7σ above trend, pressuring rate-sensitive and consumer-facing sectors like dental equipment, which could weigh on multiple expansion.

51. ?Sep 4, 4:23 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY (Dentsply Sirona) is down 21.3% from its 30-day high with no explanatory news headlines, no insider buying, no options flow, and empty metrics in the most recent 10-Q and 8-K filings — leaving the cause of the decline entirely undiagnosed. The absence of any confirmation signals (no cluster buys, no unusual call flow, no analyst commentary) means there is no identifiable recovery catalyst to anchor a high-conviction trade. Health Care is the second-ranked sector by 30-day relative strength, which is supportive at the sector level, but XRAY's idiosyncratic drop against a relatively outperforming sector is a red flag suggesting company-specific weakness rather than a sector-wide flush.

52. !Sep 4, 4:23 PMsignalseverity 0.21

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY (Dentsply Sirona) is down 21.3% from its 30-day high with no explanatory news headlines, no insider buying, no options flow, and empty metrics in the most recent 10-Q and 8-K filings — leaving the cause of the decline entirely undiagnosed. The absence of any confirmation signals (no cluster buys, no unusual call flow, no analyst commentary) means there is no identifiable recovery catalyst to anchor a high-conviction trade. Health Care is the second-ranked sector by 30-day relative strength, which is supportive at the sector level, but XRAY's idiosyncratic drop against a relatively outperforming sector is a red flag suggesting company-specific weakness rather than a sector-wide flush.

53. ?Sep 4, 2:24 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY (Dentsply Sirona) is down 21.3% from its 30-day high with no explanatory news headlines, no insider buying, no options flow, and empty metrics in the most recent 10-Q and 8-K filings — leaving the cause of the decline entirely undiagnosed. The absence of any confirmation signals (no cluster buys, no unusual call flow, no analyst commentary) means there is no identifiable recovery catalyst to anchor a high-conviction trade. Health Care is the second-ranked sector by 30-day relative strength, which is supportive at the sector level, but XRAY's idiosyncratic drop against a relatively outperforming sector is a red flag suggesting company-specific weakness rather than a sector-wide flush.

54. !Sep 4, 2:24 PMsignalseverity 0.21

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY (Dentsply Sirona) is down 21.3% from its 30-day high with no explanatory news headlines, no insider buying, no options flow, and empty metrics in the most recent 10-Q and 8-K filings — leaving the cause of the decline entirely undiagnosed. The absence of any confirmation signals (no cluster buys, no unusual call flow, no analyst commentary) means there is no identifiable recovery catalyst to anchor a high-conviction trade. Health Care is the second-ranked sector by 30-day relative strength, which is supportive at the sector level, but XRAY's idiosyncratic drop against a relatively outperforming sector is a red flag suggesting company-specific weakness rather than a sector-wide flush.

55. ?Sep 4, 1:24 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY (Dentsply Sirona) is down 21.3% from its 30-day high with no explanatory news headlines, no insider buying, no options flow, and empty metrics in the most recent 10-Q and 8-K filings — leaving the cause of the decline entirely undiagnosed. The absence of any confirmation signals (no cluster buys, no unusual call flow, no analyst commentary) means there is no identifiable recovery catalyst to anchor a high-conviction trade. Health Care is the second-ranked sector by 30-day relative strength, which is supportive at the sector level, but XRAY's idiosyncratic drop against a relatively outperforming sector is a red flag suggesting company-specific weakness rather than a sector-wide flush.

56. !Sep 4, 1:24 PMsignalseverity 0.21

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY (Dentsply Sirona) is down 21.3% from its 30-day high with no explanatory news headlines, no insider buying, no options flow, and empty metrics in the most recent 10-Q and 8-K filings — leaving the cause of the decline entirely undiagnosed. The absence of any confirmation signals (no cluster buys, no unusual call flow, no analyst commentary) means there is no identifiable recovery catalyst to anchor a high-conviction trade. Health Care is the second-ranked sector by 30-day relative strength, which is supportive at the sector level, but XRAY's idiosyncratic drop against a relatively outperforming sector is a red flag suggesting company-specific weakness rather than a sector-wide flush.

57. ?Sep 4, 12:24 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY (Dentsply Sirona) is down 21.3% from its 30-day high with no explanatory news headlines, no insider buying, no options flow, and empty metrics in the most recent 10-Q and 8-K filings — leaving the cause of the decline entirely undiagnosed. The absence of any confirmation signals (no cluster buys, no unusual call flow, no analyst commentary) means there is no identifiable recovery catalyst to anchor a high-conviction trade. Health Care is the second-ranked sector by 30-day relative strength, which is supportive at the sector level, but XRAY's idiosyncratic drop against a relatively outperforming sector is a red flag suggesting company-specific weakness rather than a sector-wide flush.

58. !Sep 4, 12:24 PMsignalseverity 0.20

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY (Dentsply Sirona) is down 21.3% from its 30-day high with no explanatory news headlines, no insider buying, no options flow, and empty metrics in the most recent 10-Q and 8-K filings — leaving the cause of the decline entirely undiagnosed. The absence of any confirmation signals (no cluster buys, no unusual call flow, no analyst commentary) means there is no identifiable recovery catalyst to anchor a high-conviction trade. Health Care is the second-ranked sector by 30-day relative strength, which is supportive at the sector level, but XRAY's idiosyncratic drop against a relatively outperforming sector is a red flag suggesting company-specific weakness rather than a sector-wide flush.

59. ❖Sep 4, 12:13 PMnewsvia finnhub

    DENTSPLY SIRONA (XRAY) Returns To Profit As Investors Weigh Its Valuation

    DENTSPLY SIRONA (XRAY) shares are in focus after the company reported second quarter 2026 results that returned the business to profitability while net sales declined 4.1% year over year. The latest results and upcoming appearance at the Baird 2026 Global Healthcare Conference come after a mixed share price pattern for DENTSPLY SIRONA, with a 7 day share price return of 3.53% but a 30 day share price return that declined 19.90%. Recent momentum has been choppy, as a 90 day share price return...

60. ❖Sep 4, 10:13 AMnewsvia finnhub

    Dentsply Sirona (XRAY) Stock May Still Trade At A Discount

    DENTSPLY SIRONA stock has had a difficult run over the past few years, yet on broad valuation checks it now screens as one of the cheaper options in its peer group. The share price history and the current multiples are sending very different signals about what the market expects from the business. Over the past 5 years, DENTSPLY SIRONA shareholders have seen the stock fall about 79.6%, which points to a long period of weak sentiment that still weighs on expectations today. The valuation...

61. ❖Sep 4, 3:20 AMnewsvia finnhub

    Does XRAY’s Profit Recovery and Reaffirmed 2026 Outlook Shift the Dentsply Sirona Thesis?

    Dentsply Sirona recently reported second-quarter 2026 results showing a 4.1% year-over-year net sales decline but a return to net income, with higher margins and stronger cash generation, and also confirmed it will present at the Baird 2026 Global Healthcare Conference on September 15, 2026. The combination of improved profitability and cash flow, despite weaker revenue and a history of pressure on returns, led management to reiterate full-year 2026 guidance, highlighting a sharper focus on...

62. ?Sep 3, 4:22 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY (Dentsply Sirona) is down 21.3% from its 30-day high with no explanatory news headlines, no insider buying, no options flow, and empty metrics in the most recent 10-Q and 8-K filings — leaving the cause of the decline entirely undiagnosed. The absence of any confirmation signals (no cluster buys, no unusual call flow, no analyst commentary) means there is no identifiable recovery catalyst to anchor a high-conviction trade. Health Care is the second-ranked sector by 30-day relative strength, which is supportive at the sector level, but XRAY's idiosyncratic drop against a relatively outperforming sector is a red flag suggesting company-specific weakness rather than a sector-wide flush.

63. !Sep 3, 4:22 PMsignalseverity 0.21

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY (Dentsply Sirona) is down 21.3% from its 30-day high with no explanatory news headlines, no insider buying, no options flow, and empty metrics in the most recent 10-Q and 8-K filings — leaving the cause of the decline entirely undiagnosed. The absence of any confirmation signals (no cluster buys, no unusual call flow, no analyst commentary) means there is no identifiable recovery catalyst to anchor a high-conviction trade. Health Care is the second-ranked sector by 30-day relative strength, which is supportive at the sector level, but XRAY's idiosyncratic drop against a relatively outperforming sector is a red flag suggesting company-specific weakness rather than a sector-wide flush.

64. ❖Sep 3, 4:15 PMnewsvia finnhub

    Dentsply Sirona to Participate in the Baird 2026 Global Healthcare Conference

    CHARLOTTE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the Baird 2026 Global Healthcare Conference. Management is scheduled to present on Tuesday, September 15, 2026, at 11:25 a.m. ET. Investors and other interested parties will be able to access a live audio webcast and an audio webcast replay by visiting the Investors section of the Dentsply Sirona website at https://inves

65. ?Sep 3, 3:22 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY (Dentsply Sirona) is down 21.3% from its 30-day high with no explanatory news headlines, no insider buying, no options flow, and empty metrics in the most recent 10-Q and 8-K filings — leaving the cause of the decline entirely undiagnosed. The absence of any confirmation signals (no cluster buys, no unusual call flow, no analyst commentary) means there is no identifiable recovery catalyst to anchor a high-conviction trade. Health Care is the second-ranked sector by 30-day relative strength, which is supportive at the sector level, but XRAY's idiosyncratic drop against a relatively outperforming sector is a red flag suggesting company-specific weakness rather than a sector-wide flush.

66. !Sep 3, 3:22 PMsignalseverity 0.21

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY (Dentsply Sirona) is down 21.3% from its 30-day high with no explanatory news headlines, no insider buying, no options flow, and empty metrics in the most recent 10-Q and 8-K filings — leaving the cause of the decline entirely undiagnosed. The absence of any confirmation signals (no cluster buys, no unusual call flow, no analyst commentary) means there is no identifiable recovery catalyst to anchor a high-conviction trade. Health Care is the second-ranked sector by 30-day relative strength, which is supportive at the sector level, but XRAY's idiosyncratic drop against a relatively outperforming sector is a red flag suggesting company-specific weakness rather than a sector-wide flush.

67. ?Sep 3, 1:23 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY (Dentsply Sirona) is down 21.3% from its 30-day high with no explanatory news headlines, no insider buying, no options flow, and empty metrics in the most recent 10-Q and 8-K filings — leaving the cause of the decline entirely undiagnosed. The absence of any confirmation signals (no cluster buys, no unusual call flow, no analyst commentary) means there is no identifiable recovery catalyst to anchor a high-conviction trade. Health Care is the second-ranked sector by 30-day relative strength, which is supportive at the sector level, but XRAY's idiosyncratic drop against a relatively outperforming sector is a red flag suggesting company-specific weakness rather than a sector-wide flush.

68. ?Sep 3, 11:25 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY (Dentsply Sirona) is down 21.3% from its 30-day high with no explanatory news headlines, no insider buying, no options flow, and empty metrics in the most recent 10-Q and 8-K filings — leaving the cause of the decline entirely undiagnosed. The absence of any confirmation signals (no cluster buys, no unusual call flow, no analyst commentary) means there is no identifiable recovery catalyst to anchor a high-conviction trade. Health Care is the second-ranked sector by 30-day relative strength, which is supportive at the sector level, but XRAY's idiosyncratic drop against a relatively outperforming sector is a red flag suggesting company-specific weakness rather than a sector-wide flush.

69. ❖Sep 3, 6:38 AMnewsvia finnhub

    Dentsply Sirona (XRAY) Swings Back To Profit While Sales Keep Sliding

    On August 6, Dentsply Sirona (NASDAQ:XRAY) reported second-quarter 2026 results that pulled the stock in two directions at once. Net sales fell 4.1% year over year to $898 million, yet the company swung from a $45 million net loss a year earlier to $37 million in net income, with diluted earnings per share of $0.18 […]

70. ❖Sep 3, 4:31 AMnewsvia finnhub

    1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds

    Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 25.1% over the past six months, topping the S&P 500 by 13.1 percentage points.

71. ?Sep 2, 4:23 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY (Dentsply Sirona) is down 21.3% from its 30-day high with no explanatory news headlines, no insider buying, no options flow, and empty metrics in the most recent 10-Q and 8-K filings — leaving the cause of the decline entirely undiagnosed. The absence of any confirmation signals (no cluster buys, no unusual call flow, no analyst commentary) means there is no identifiable recovery catalyst to anchor a high-conviction trade. Health Care is the second-ranked sector by 30-day relative strength, which is supportive at the sector level, but XRAY's idiosyncratic drop against a relatively outperforming sector is a red flag suggesting company-specific weakness rather than a sector-wide flush.

72. ?Sep 2, 3:35 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    With only 10 minutes remaining until the forced 3:45 PM ET close, there is virtually no runway for this move to extend meaningfully. The 5.39% gain is substantial and represents real conviction, but at this stage the dominant risk is profit-taking and mean reversion into the close rather than continuation. No supporting news catalyst is present to sustain buying interest. The macro context (elevated 5Y5Y inflation forward rate at 1.7σ above trend) is modestly unfavorable for rate-sensitive sectors, and dental/healthcare equipment names like XRAY can be sensitive to rate expectations. With the position forced flat in 10 minutes, the asymmetry of a +3% target vs. -1.5% stop is insufficient to overcome the time constraint — there is simply not enough time for the trade to reach the profit target even if direction is correct. Time decay on the setup is the primary driver of the below-0.5 probability.

73. ?Sep 2, 3:24 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY (Dentsply Sirona) is down 21.3% from its 30-day high with no explanatory news headlines, no insider buying, no options flow, and empty metrics in the most recent 10-Q and 8-K filings — leaving the cause of the decline entirely undiagnosed. The absence of any confirmation signals (no cluster buys, no unusual call flow, no analyst commentary) means there is no identifiable recovery catalyst to anchor a high-conviction trade. Health Care is the second-ranked sector by 30-day relative strength, which is supportive at the sector level, but XRAY's idiosyncratic drop against a relatively outperforming sector is a red flag suggesting company-specific weakness rather than a sector-wide flush.

74. ?Sep 2, 11:25 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    XRAY is up 5.76% with no attributable headline, suggesting this is flow-driven or sector-rotation-driven rather than a catalytic news event. With 260 minutes remaining there is ample time for the move to extend, which is a mild positive. However, a 5.76% move without a clear fundamental catalyst raises mean-reversion risk — large moves absent news tend to fade more often than smaller conviction moves with a clear driver. The macro backdrop (5Y5Y inflation forward 1.7σ above trend) is mildly unhelpful for a rate-sensitive or consumer-discretionary name like XRAY (dental), as elevated inflation expectations could pressure margins and dampen risk appetite in the sector. No reversal signal is visible, and no volume data suggests thinness, so there is no strong reason to call a fade. Net: modest continuation lean given time remaining and absence of reversal evidence, but below a high-conviction threshold given the outsized move without a catalyst.

75. ?Sep 2, 7:06 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY (Dentsply Sirona) is down 25.5% from its 30-day high with no explanatory news headlines, no meaningful SEC filing metrics, and no insider buying activity to signal confidence from insiders. The 10-Q and 8-K filed on 2026-08-06 are empty of financial metrics, leaving the fundamental picture opaque. Without a clear catalyst for the drop or a confirmed overreaction narrative, it is difficult to characterize this as a clean dip-buy setup. The Healthcare sector is relatively strong (rank 2/11, +3.73pts vs SPY over 30d), which means XRAY's drop appears idiosyncratic rather than sector-driven — a yellow flag suggesting company-specific impairment. The broad market is risk-off today (SPY -0.69%, VXX +3.17%), further compressing near-term rebound potential.

76. ?Sep 1, 4:23 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY (Dentsply Sirona) is down 25.5% from its 30-day high with no explanatory news headlines, no meaningful SEC filing metrics, and no insider buying activity to signal confidence from insiders. The 10-Q and 8-K filed on 2026-08-06 are empty of financial metrics, leaving the fundamental picture opaque. Without a clear catalyst for the drop or a confirmed overreaction narrative, it is difficult to characterize this as a clean dip-buy setup. The Healthcare sector is relatively strong (rank 2/11, +3.73pts vs SPY over 30d), which means XRAY's drop appears idiosyncratic rather than sector-driven — a yellow flag suggesting company-specific impairment. The broad market is risk-off today (SPY -0.69%, VXX +3.17%), further compressing near-term rebound potential.

77. ?Aug 31, 4:23 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 24.2% from its 30-day high with only a single mildly negative news headline and empty 10-Q/8-K metric blocks, leaving the cause of the drop largely opaque. The absence of insider buying, no options flow confirmation, and no identifiable positive catalyst (next earnings are 72 days out) leave no strong recovery thesis. At ~$10.95 and trading near multi-year lows, the stock may be cheap on an absolute basis, but Dentsply Sirona has a well-documented history of guidance cuts, margin pressure, and secular headwinds in dental equipment demand — suggesting the drop may reflect genuine fundamental deterioration rather than a temporary overreaction. Health Care sector showed slight underperformance on the 30-day basis (-0.99 vs SPY), reducing the likelihood this is purely a sector-wide dislocation that will self-correct.

78. ?Aug 31, 3:24 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 24.2% from its 30-day high with only a single mildly negative news headline and empty 10-Q/8-K metric blocks, leaving the cause of the drop largely opaque. The absence of insider buying, no options flow confirmation, and no identifiable positive catalyst (next earnings are 72 days out) leave no strong recovery thesis. At ~$10.95 and trading near multi-year lows, the stock may be cheap on an absolute basis, but Dentsply Sirona has a well-documented history of guidance cuts, margin pressure, and secular headwinds in dental equipment demand — suggesting the drop may reflect genuine fundamental deterioration rather than a temporary overreaction. Health Care sector showed slight underperformance on the 30-day basis (-0.99 vs SPY), reducing the likelihood this is purely a sector-wide dislocation that will self-correct.

79. ?Aug 31, 2:24 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 24.2% from its 30-day high with only a single mildly negative news headline and empty 10-Q/8-K metric blocks, leaving the cause of the drop largely opaque. The absence of insider buying, no options flow confirmation, and no identifiable positive catalyst (next earnings are 72 days out) leave no strong recovery thesis. At ~$10.95 and trading near multi-year lows, the stock may be cheap on an absolute basis, but Dentsply Sirona has a well-documented history of guidance cuts, margin pressure, and secular headwinds in dental equipment demand — suggesting the drop may reflect genuine fundamental deterioration rather than a temporary overreaction. Health Care sector showed slight underperformance on the 30-day basis (-0.99 vs SPY), reducing the likelihood this is purely a sector-wide dislocation that will self-correct.

80. ?Aug 28, 4:22 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 24.2% from its 30-day high with only a single mildly negative news headline and empty 10-Q/8-K metric blocks, leaving the cause of the drop largely opaque. The absence of insider buying, no options flow confirmation, and no identifiable positive catalyst (next earnings are 72 days out) leave no strong recovery thesis. At ~$10.95 and trading near multi-year lows, the stock may be cheap on an absolute basis, but Dentsply Sirona has a well-documented history of guidance cuts, margin pressure, and secular headwinds in dental equipment demand — suggesting the drop may reflect genuine fundamental deterioration rather than a temporary overreaction. Health Care sector showed slight underperformance on the 30-day basis (-0.99 vs SPY), reducing the likelihood this is purely a sector-wide dislocation that will self-correct.

81. ?Aug 28, 3:24 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 24.2% from its 30-day high with only a single mildly negative news headline and empty 10-Q/8-K metric blocks, leaving the cause of the drop largely opaque. The absence of insider buying, no options flow confirmation, and no identifiable positive catalyst (next earnings are 72 days out) leave no strong recovery thesis. At ~$10.95 and trading near multi-year lows, the stock may be cheap on an absolute basis, but Dentsply Sirona has a well-documented history of guidance cuts, margin pressure, and secular headwinds in dental equipment demand — suggesting the drop may reflect genuine fundamental deterioration rather than a temporary overreaction. Health Care sector showed slight underperformance on the 30-day basis (-0.99 vs SPY), reducing the likelihood this is purely a sector-wide dislocation that will self-correct.

82. ?Aug 27, 4:22 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 24.2% from its 30-day high with only a single mildly negative news headline and empty 10-Q/8-K metric blocks, leaving the cause of the drop largely opaque. The absence of insider buying, no options flow confirmation, and no identifiable positive catalyst (next earnings are 72 days out) leave no strong recovery thesis. At ~$10.95 and trading near multi-year lows, the stock may be cheap on an absolute basis, but Dentsply Sirona has a well-documented history of guidance cuts, margin pressure, and secular headwinds in dental equipment demand — suggesting the drop may reflect genuine fundamental deterioration rather than a temporary overreaction. Health Care sector showed slight underperformance on the 30-day basis (-0.99 vs SPY), reducing the likelihood this is purely a sector-wide dislocation that will self-correct.

83. ?Aug 27, 3:23 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 24.2% from its 30-day high with only a single mildly negative news headline and empty 10-Q/8-K metric blocks, leaving the cause of the drop largely opaque. The absence of insider buying, no options flow confirmation, and no identifiable positive catalyst (next earnings are 72 days out) leave no strong recovery thesis. At ~$10.95 and trading near multi-year lows, the stock may be cheap on an absolute basis, but Dentsply Sirona has a well-documented history of guidance cuts, margin pressure, and secular headwinds in dental equipment demand — suggesting the drop may reflect genuine fundamental deterioration rather than a temporary overreaction. Health Care sector showed slight underperformance on the 30-day basis (-0.99 vs SPY), reducing the likelihood this is purely a sector-wide dislocation that will self-correct.

84. ?Aug 27, 2:26 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 24.2% from its 30-day high with only a single mildly negative news headline and empty 10-Q/8-K metric blocks, leaving the cause of the drop largely opaque. The absence of insider buying, no options flow confirmation, and no identifiable positive catalyst (next earnings are 72 days out) leave no strong recovery thesis. At ~$10.95 and trading near multi-year lows, the stock may be cheap on an absolute basis, but Dentsply Sirona has a well-documented history of guidance cuts, margin pressure, and secular headwinds in dental equipment demand — suggesting the drop may reflect genuine fundamental deterioration rather than a temporary overreaction. Health Care sector showed slight underperformance on the 30-day basis (-0.99 vs SPY), reducing the likelihood this is purely a sector-wide dislocation that will self-correct.

85. ?Aug 27, 1:26 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 24.2% from its 30-day high with only a single mildly negative news headline and empty 10-Q/8-K metric blocks, leaving the cause of the drop largely opaque. The absence of insider buying, no options flow confirmation, and no identifiable positive catalyst (next earnings are 72 days out) leave no strong recovery thesis. At ~$10.95 and trading near multi-year lows, the stock may be cheap on an absolute basis, but Dentsply Sirona has a well-documented history of guidance cuts, margin pressure, and secular headwinds in dental equipment demand — suggesting the drop may reflect genuine fundamental deterioration rather than a temporary overreaction. Health Care sector showed slight underperformance on the 30-day basis (-0.99 vs SPY), reducing the likelihood this is purely a sector-wide dislocation that will self-correct.

86. ?Aug 27, 11:51 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    XRAY is up 1.88% today with no identifiable news catalyst. The move is modest — below the 2-5% threshold where conviction flow becomes highly informative — so it could reflect routine rotation or market-wide drift rather than stock-specific accumulation. Macro context shows 5-year forward inflation expectations (T5YIFR) elevated at 1.6σ above trend, which is mildly unfavorable for rate-sensitive and debt-heavy sectors; XRAY as a dental products company with moderate leverage is somewhat exposed to rate-sensitive headwinds, creating a mild fade risk. However, absence of news is not a disqualifier, and with 235 minutes remaining there is ample session time for the move to extend if underlying flow is real. No reversal signal or fade pattern is evident from the data provided. On balance, the setup is borderline — ordinary low-catalyst momentum with a slight macro headwind — warranting a minimal continuation edge just above the 0.5 threshold.

87. ?Aug 27, 10:06 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    XRAY is up 1.78% today, a modest but real move suggesting some underlying buy flow. There are no headlines to explain the move, which is common and not disqualifying. With 340 minutes remaining (roughly equivalent to a full trading session ahead of the 3:45 ET cutoff), there is ample time for continuation if momentum holds. The macro context shows the 5-year forward inflation rate (T5YIFR) elevated at 1.6σ above trend — XRAY (dental equipment/healthcare) is not a primary rate-sensitive sector, so this macro signal is largely neutral here rather than a headwind or tailwind. Without a catalyst, volume confirmation, or sector tailwind, this reads as ordinary momentum — no strong reason to expect fade, but also no clear continuation pressure. Assigning the threshold probability of 0.5 to reflect a borderline but actionable setup consistent with the system's bias toward participation when no fade signal is present.

88. ?Aug 27, 7:06 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 24.2% from its 30-day high with only a single mildly negative news headline and empty 10-Q/8-K metric blocks, leaving the cause of the drop largely opaque. The absence of insider buying, no options flow confirmation, and no identifiable positive catalyst (next earnings are 72 days out) leave no strong recovery thesis. At ~$10.95 and trading near multi-year lows, the stock may be cheap on an absolute basis, but Dentsply Sirona has a well-documented history of guidance cuts, margin pressure, and secular headwinds in dental equipment demand — suggesting the drop may reflect genuine fundamental deterioration rather than a temporary overreaction. Health Care sector showed slight underperformance on the 30-day basis (-0.99 vs SPY), reducing the likelihood this is purely a sector-wide dislocation that will self-correct.

89. ❖Aug 24, 6:17 AMnewsvia finnhub

    Barclays Maintains Underweight on Dentsply Sirona, Raises Price Target to $11

    Barclays analyst Glen Santangelo maintains Dentsply Sirona (NASDAQ:XRAY) with a Underweight and raises the price target from $9 to $11.

90. ❖Aug 11, 12:13 AMnewsvia finnhub

    Why Dentsply Sirona (XRAY) Stock Is Trading Lower Today

    Shares of dental products company Dentsply Sirona (NASDAQ:XRAY) fell 6.8% in the afternoon session after the company reported second-quarter 2026 earnings, which featured a beat on profit estimates, was overshadowed by a weak full-year revenue forecast.

91. ❖Aug 7, 5:04 PMnewsvia finnhub

    DENTSPLY SIRONA Q2 Earnings Call Highlights

    DENTSPLY SIRONA (NASDAQ:XRAY) reported second-quarter 2026 revenue of $898 million, down 4.1% on a reported basis and 6.3% on a constant-currency basis, as the dental products company continued its turnaround plan amid lower volumes in several businesses and distributor inventory reductions in Europ

92. ❖Aug 7, 4:13 PMnewsvia finnhub

    1% Undervalued? DENTSPLY SIRONA (XRAY) As Earnings Test Its Recovery Story

    Earnings trigger and recent business updates DENTSPLY SIRONA (XRAY) is in focus after reporting second quarter 2026 earnings on 6 August, alongside reaffirmed full year net sales guidance and an update on long running share repurchases. The company reported quarterly sales of US$898 million compared with US$936 million a year earlier. Net income for the quarter was US$37 million compared with a net loss of US$45 million in the prior year period, with basic and diluted earnings per share from...

93. ❖Aug 7, 2:35 PMnewsvia finnhub

    XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales

    DENTSPLY SIRONA's Q2 sales fall 4.1% as dental weakness offsets Wellspect growth, while margins improve and 2026 guidance is maintained.

94. ❖Aug 7, 9:30 AMnewsvia finnhub

    Here's What Key Metrics Tell Us About Dentsply (XRAY) Q2 Earnings

    The headline numbers for Dentsply (XRAY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

95. ❖Aug 6, 7:02 PMnewsvia finnhub

    DENTSPLY SIRONA Inc. 2026 Q2 - Results - Earnings Call Presentation

    2026-08-06. The following slide deck was published by DENTSPLY SIRONA Inc.

96. ❖Aug 6, 5:40 PMnewsvia finnhub

    Dentsply International (XRAY) Beats Q2 Earnings and Revenue Estimates

    Dentsply (XRAY) delivered earnings and revenue surprises of +44.44% and +1.60%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

97. ❖Aug 6, 4:54 PMnewsvia finnhub

    DENTSPLY SIRONA Inc. (XRAY) Q2 2026 Earnings Call Transcript

    DENTSPLY SIRONA Inc. (XRAY) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsWade Moody - Senior Manager of Investor RelationsDaniel...

98. ❖Aug 6, 4:37 PMnewsvia finnhub

    Dentsply Sirona (NASDAQ:XRAY) Beats Q2 CY2026 Sales Expectations

    Dental products company Dentsply Sirona (NASDAQ:XRAY) reported Q2 CY2026 results topping the market’s revenue expectations, but sales fell by 4.1% year on year to $898 million. On the other hand, the company’s full-year revenue guidance of $3.55 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $0.52 per share was 50.1% above analysts’ consensus estimates.

99. ❖Aug 6, 4:01 PMnewsvia finnhub

    Dentsply Sirona Reports Second Quarter 2026 Results

    News Summary Reported net sales of $898 millionDelivered GAAP gross margin of 54.9%, GAAP diluted earnings per share of $0.18Achieved adjusted gross margin of 56.4%, adjusted EBITDA margin of 21.3%, adjusted EPS of $0.52Announced expanded partnership with Medline Sinclair, broadening access to Connected Technology Solutions portfolio across CanadaRepurchased 1.3 million shares of common stock during the quarterReiterates 2026 outlook for net sales and adjusted EPS CHARLOTTE, N.C., Aug. 06, 2026

100. ❖Aug 6, 12:08 PMnewsvia finnhub

     Dentsply Sirona Affirms FY2026 Adj EPS Guidance of $1.40-$1.50 vs $1.42 Est; Affirms FY2026 Sales Guidance of $3.500B-$3.600B vs $3.582B Est

     Dentsply Sirona (NASDAQ:XRAY) affirms FY2026 Adj EPS guidance from $1.40-$1.50 to $1.40-$1.50 vs $1.42 analyst estimate. Affirms FY2026 sales outlook from $3.500 billion-$3.600 billion to $3.500 billion-$3.600 billion

101. ❖Aug 6, 12:04 PMnewsvia finnhub

     Dentsply Sirona Q2 Adj. EPS $0.52 Beats $0.35 Estimate, Sales $898.000M Beat $889.810M Estimate

     Dentsply Sirona (NASDAQ:XRAY) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $0.35 by 48.57 percent. This is unchanged from the same period last year. The company reported

102. ❖Aug 4, 12:22 PMnewsvia finnhub

     DENTSPLY SIRONA to Post Q2 Earnings: What's in Store for the Stock?

     XRAY's Q2 results are likely to reflect transformation investments, dealer inventory cuts and weak implants, while Wellspect growth offers support.

103. ❖Aug 3, 11:07 AMnewsvia finnhub

     Can Dentsply Sirona (XRAY) Turn Its Business Around?

     Ariel Investments, an investment management company, released its “Ariel Focus Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The Fund returned 2.14% in the second quarter of 2026, underperforming the Russell 1000 Value and S&P 500, which gained 13.87% and 15.20%, respectively. The fund benefited from gains in several […]

104. ❖Jul 29, 9:17 AMnewsvia finnhub

     Piper Sandler Maintains Neutral on Dentsply Sirona, Raises Price Target to $14

     Piper Sandler analyst Jason Bednar maintains Dentsply Sirona (NASDAQ:XRAY) with a Neutral and raises the price target from $13 to $14.

105. ❖Jul 28, 8:30 AMnewsvia finnhub

     Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship

     The expansion marks Dentsply Sirona's sixth dealer network enhancement announced in 2026, further advancing its strategy to broaden access to digital dentistry solutions through trusted distribution partnersCHARLOTTE, N.C., July 28, 2026 (GLOBE NEWSWIRE) -- Dentsply Sirona, the world's largest diversified manufacturer of professional dental products and technologies, today announced an expansion of its long-standing relationship with Medline Sinclair, one of Canada's leading full-service dental

106. ❖Jul 24, 2:57 PMnewsvia finnhub

     3 Reasons to Sell XRAY and 1 Stock to Buy Instead

     Dentsply Sirona has been treading water for the past six months, recording a small loss of 0.5% while holding steady at $12.66. The stock also fell short of the S&P 500’s 7.9% gain during that period.

107. ❖Jul 21, 4:15 PMnewsvia finnhub

     Dentsply Sirona to Host Second Quarter Conference Call on August 6th

     CHARLOTTE, N.C., July 21, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, August 6, 2026, at 4:30 p.m. ET to review its second quarter 2026 financial results. Financial earnings materials will be made available on the Investors section of the Company’s website at https://investor.dentsplysirona.com prior to the call. Conference Call / Webcast Info

108. ❖Jul 19, 9:52 PMnewsvia finnhub

     Ariel Focus Fund Q2 2026 Portfolio Activity

     Boutique asset manager, Affiliated Managers Group, Inc. advanced during the quarter, with strong momentum in its alternatives platform. Read more here.

109. ❖Jul 13, 9:26 AMnewsvia finnhub

     Q2 2026 Earnings Preview: Navigating High Expectations, Tariff Rebates, And War Uncertainties

     Wall Street analysts expect Q2 S&P 500 profit growth of 23.6%, which could mark the 7th consecutive quarter of double-digit earnings growth.

110. ❖Jul 10, 7:03 AMnewsvia finnhub

     Solving A Lackluster Growth Outlook Should Be Solventum's Next Priority

     Solventum Corporation trades at a discount with 20%+ upside from restructuring and portfolio moves despite slow growth. Click for this SOLV update.

111. ❖Jul 9, 6:25 AMnewsvia finnhub

     BMO Capital Initiates Coverage On Dentsply Sirona with Market Perform Rating, Announces Price Target of $12

     BMO Capital initiates coverage on Dentsply Sirona (NASDAQ:XRAY) with a Market Perform rating and announces Price Target of $12.

112. ❖Jul 7, 8:35 AMnewsvia finnhub

     Dentsply Sirona: The Recovery Story Needs More Than A Stock Rebound

     DENTSPLY SIRONA recovery watch: Q1 sales -6.7%, margin 14.7%, FCF -$12M. Click for more on XRAY stock.

113. ❖Jul 7, 5:42 AMnewsvia finnhub

     DENTSPLY SIRONA Inc. (XRAY)’s Shares Are Flat Since Cramer Commented On Them

     We recently published Jim Cramer’s Biggest Losers: 10 Stocks That Just Didn’t Work Out. DENTSPLY SIRONA Inc. (NASDAQ:XRAY) is one of the stocks discussed by Jim Cramer. DENTSPLY SIRONA Inc. (NASDAQ:XRAY) is a dental products manufacturer. Its shares are down by 26.9% over the past year and are up by 3.4% year-to-date. Soon after Cramer […]

114. ❖Jul 1, 5:00 PMnewsvia finnhub

     PDS Health Surpasses Five Million CEREC Chairside Restorations with Dentsply Sirona, Marking a Major Milestone in Scaled Digital Dentistry

     This milestone reflects PDS Health’s continued investment in digital technologies that help practices operate more efficiently, expand access to same-day restorative care and deliver a more consistent experience for patients.CHARLOTTE, N.C., July 01, 2026 (GLOBE NEWSWIRE) -- PDS Health® and Dentsply Sirona today announced that PDS Health practices have surpassed five million CEREC chairside restorations, a milestone that underscores the scale, consistency and long-term integration of digital res

115. ▣Jun 29, 8:00 PMjournalstop

     options_momentum closed long 800 @ $0.35 (-$118.90)

     Stop: premium $0.35 ≤ trailing floor $0.44 (peak $0.59 × 0.75)

116. ▢Jun 24, 8:00 PMjournal

     options_momentum opened long 800 @ $0.50

117. ❖Jun 24, 8:08 AMnewsvia finnhub

     Dental Equipment & Technology Stocks Q1 In Review: Dentsply Sirona (NASDAQ:XRAY) Vs Peers

     Wrapping up Q1 earnings, we look at the numbers and key takeaways for the dental equipment & technology stocks, including Dentsply Sirona (NASDAQ:XRAY) and its peers.

118. ▢Jun 16, 8:00 PMjournal

     options_momentum opened long 1,300 @ $0.32

119. ▣Jun 16, 8:00 PMjournalstop

     options_momentum closed long 1,300 @ $0.23 (-$116.89)

     Stop: premium $0.23 ≤ trailing floor $0.24 (peak $0.32 × 0.75)

120. ❖Jun 16, 1:53 PMnewsvia finnhub

     3 Small-Cap Stocks We Think Twice About

     Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

121. ❖Jun 15, 12:18 AMnewsvia finnhub

     How DENTSPLY SIRONA’s New Veteran CFO Could Shape Capital Allocation and Strategy for XRAY Investors

     DENTSPLY SIRONA has appointed John C. Fortson as Executive Vice President and Chief Financial Officer, effective July 20, 2026, bringing decades of experience in executive finance roles across industrial and materials companies and a background in investment banking and military service. This hire introduces a finance leader with prior CEO and CFO experience in complex, global manufacturing businesses, which may influence how DENTSPLY SIRONA approaches capital allocation, operational...

122. ▣Jun 10, 8:00 PMjournalstop

     options_momentum closed long 800 @ $0.40 (-$138.36)

     Stop: premium $0.40 ≤ trailing floor $0.43 (peak $0.57 × 0.75)

123. ▣Jun 9, 8:00 PMjournalstop

     options_momentum closed long 600 @ $0.56 (-$122.23)

     Stop: premium $0.56 ≤ trailing floor $0.57 (peak $0.76 × 0.75)

124. ▢Jun 9, 8:00 PMjournal

     options_momentum opened long 800 @ $0.57

125. ❖Jun 9, 6:54 AMnewsvia finnhub

     3 Unprofitable Stocks That Fall Short

     Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

126. ▢Jun 8, 8:00 PMjournal

     options_momentum opened long 600 @ $0.76

127. ▣May 25, 8:00 PMjournalmanual

     options_momentum closed long 4,200 @ $0.26 (+$52.27)

     Stop: premium $0.23 ≤ trailing floor $0.38 (peak $0.51 × 0.75)

128. ❖May 17, 5:40 AMnewsvia finnhub

     Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know

     A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with service-sector prices rising at their fastest pace in four years.

129. ▢May 13, 8:00 PMjournal

     options_momentum opened long 4,200 @ $0.25